

# Introduction & Notes re: MVB Annual Assessment Setting Workbook

MVB Calendar Year 2021

[Note: This is Working Version as of 9/22/2020.

01. This workbook follows the past naming conventions with each sheet beginning with a letter (i.e., "a." through "d."), and each cell within each sheet being identified by a 2-digit row number (e.g., "01.") and column letter (e.g., "A"). So, to facilitate reference while collaborating via conference phone, users can refer to any single number, for example the new assessment rate, by a combination of the above. For that key number, the new monthly assessment rate, the reference is "a.26.C".
02. Since the first measurement period is for the month of January and assessments are due forty-five (45) days after the end of each quarter, the first assessment payment with the new rate will be May 15, 2021 for the months of Jan-Mar, 2021.
03. The primary spreadsheet for the work is the assessment calculation worksheet, worksheet a. The other sheets are intended to be reference or to develop background data in specific areas for the work. Key data for developing the primary funding target is on spreadsheet b. which contains data supplied by the Maine CDC for the vaccine funding needs. Key numbers from a subsidiary sheet rolled into the main assessment sheet generally are shaded in yellow. *For the 2021 calculations a standard State FY 2021 CDC forecast was not available. It is uncertain when the federal projection tool will be available so an inflation approach was used. Column J of tab b. was used to populate April 2020 CDC cost per dose amounts and this was applied to the State FY2020 number of projected doses in order to project State FY2021 costs which are in column K.*
04. These spreadsheets have Board controls. This is intended to help users test various assumptions and control points which may be adjusted by the MVB in setting the final new rate. Those cells in which entries normally would be made are shaded in green. For example, a user can adjust utilization assumptions for increases over prior years by entering percent's either by vaccine on sheet b. or overall on sheet a (a.3.D). The vaccine funding target takes the number as adjusted by those two factors and then applies the assumed cost increase (a.4.D). The cost increase is applied for 9/12 of the year since it typically becomes effective as of April 1 each year.
05. Because the first collections of the year (due February 15) will still be at the old rate and based upon covered lives reported for Oct-Dec 2020, this spreadsheet first deducts that quarterly collection and then calculates the new rate based upon what is needed to hit the funding target over the remaining 9 months.
06. It is anticipated that the MVB will, as part of its deliberations and upon considering the input of any public members or others at its meeting(s), adjust the assumptions which guide the assessment level. Of course, the MVB may also determine to adjust the assessment setting process itself or this workbook structure at any time.

# Maine Vaccine Board

## 2021 Calendar Year Assessment Calculation

Column →	A	B	C	D	E
Line ↓	2020		2021		
<b>A. Preliminary Vaccine Cost, Projection Parameters, &amp; Population Estimates</b>					
01.	\$13,627,265		\$14,258,134		State Fiscal Year Vaccine Estimate (from tab b.)
02.	139,739		139,371		Estimate of Covered Lives ( <b>Covered Lives tab c.</b> )
03.	\$136,273	1.0%	\$142,581	1.0%	Provision for Vaccine Utilization increase
04.	\$227,098	2.2%	\$486,024	4.5%	Vaccine cost inflation factor (prices change each April 1st)
05.	\$13,990,636		\$14,886,740		<sup>1</sup> Calendar Year Vaccine Funding Estimate
<b>B. Budget Estimates</b>					
06.	\$149,040		\$152,021		<sup>3</sup> Servicing Agent Contract for Administrative Services
07.	\$6,000		\$7,000		Audit Fee (Move to paid public auditor )
08.	\$7,000		\$7,252		Bank Fees (adding TD Bank Lockbox including setup expenses)
09.	\$10,500		\$10,500		Legal (services of AG's office only estimated)
10.	\$172,540		\$176,773		Total Operating Costs Projected
<b>C. Financial Carry Forwards</b>					
11.	\$6,647,318		\$6,582,936		Estimated Starting Balance January 1
12.	\$3,284,574	3.0	\$3,508,078	3.00	Amount Retained for Liquidity Reserve - 3.0 months of non flu
13.	\$852,342		\$854,426		Amount Retained for Liquidity Reserve - full annual flu cost
14.	\$2,510,402		\$2,220,431		Carryforward used to reduce current assessment calculation
<b>D. Aggregate Annual Assessment Calculation</b>					
15.	\$13,990,636		\$14,886,740		Costs of Vaccines Provided
16.	\$172,540		\$176,773		Total Operating Costs
17.	\$0		\$0		Other (as approved by board -- see statute section 2.M)
18.	\$14,163,176		\$15,063,513		"Total Costs of the Fund" per statute section 2.M.
19.	\$49,571	0.35%	\$52,722	0.35%	Collection Losses (i.e. assumed "bad debt expense")
20.	-\$104,845		-\$113,253		<sup>2</sup> Interest Income
21.	-\$2,510,402	-17.7%	-\$2,220,431	-14.7%	(excess) or shortfall of cash from prior operating year
22.	\$318,671	2.25%	\$527,223	3.50%	add reserve up to 10% per statute section 5.A.(3).
23.	\$11,916,171		\$13,309,774		Total Assessments Needed
24.	-\$1,910,462		-\$3,326,463		Projected assessments February 15 at old rate
25.	\$10,005,709		\$9,983,311		Total Assessments Needed at new rate
<b>E. Per Covered Life Assessment Calculation</b>					
26.	\$95.47		\$95.51		<b>Annual Assessment per Covered Life</b>
27.	\$7.96		\$7.96		<b>Monthly Assessment per Covered Life</b>
28.	20.3%		4.6%		% Change in Vaccine Costs
29.	74.58%		0.0%		% Change in Assessment
<b>F. Note: Total Assessed as % of Hard Vaccine Costs</b>					
30.	-14.83%		-10.6%		All-in costs % above vaccine costs
<b>G. Indicated Monthly Assessment Level next year apart from reserve / cash changes</b>					
31.	\$8.93		\$9.99		<sup>4</sup> Preliminary Assessment projection
<b>Notes</b>					
			25.6%		Increase in preliminary assessment projection

<sup>1</sup> Maine CDC + per vaccine adjustments + utilization increase with inflation factor.

<sup>2</sup> Used the average of the six most recent year's Investment Income from audited financials.

<sup>3</sup> Fixed price contract all inclusive of expenses.

<sup>4</sup> Projection: annual amounts w/ carryforward cash, reserve changes, and 1 more year of inflation & utilization changes.

Maine CDC Vaccine Projection Data

Column →  
Line ↓

	A	B	C	D	E	F	G	H	I	J	K	
	Vaccine	Brand Name	NDC	Prior Year Actuals			Federal FY 20 Estimates			Federal FY 21 Estimates		Vaccine Funding Target
				Cost Per Dose	Doses	Cost	Cost Per Dose	Doses	Cost	Cost Per Dose		
01.	DAPTACEL	Sanofi Pastuer	49281-0286-10	\$ 17.61	4018	\$ 70,756.98	\$18.07	6,765	\$122,244	\$18.55	\$125,491	
1.b				\$ 18.07	1141	\$ 20,617.87						
02.	PENTACEL	Sanofi Pastuer	49281-0510-05	\$ 58.33	7652	\$ 446,341.16	\$59.42	9,940	\$590,635	\$61.65	\$612,801	
2.b				\$ 59.42	2626	\$ 156,036.92						
03.	QUADRACEL	Sanofi Pastuer	49281-0562-10	\$ 39.57	1581	\$ 62,560.17	\$40.67	1,858	\$75,565	\$41.80	\$77,664	
3.b				\$ 40.67	823	\$ 33,471.41						
04.	IPOL (EIPV)	Sanofi Pastuer	49281-0860-10	\$ 13.30	1690	\$ 22,477.00	\$13.55	4,118	\$55,799	\$13.85	\$57,034	
4.b				\$ 13.55	684	\$ 9,268.20						
05.	Menactra (MCV4)	Sanofi Pastuer	49281-0589-05	\$ 91.81	9056	\$ 831,431.36	\$93.45	19,822	\$1,852,366	\$96.23	\$1,907,471	
5.b				\$ 93.45	2536	\$ 236,989.20						
06.	ACTHIB (HIB)	Sanofi Pastuer	49281-0545-03	\$ 9.23	4177	\$ 38,553.71	\$9.48	6,577	\$62,350	\$9.75	\$64,126	
				\$ 9.48	1557	\$ 14,760.36						
07.	ADACEL (Tdap)	Sanofi Pastuer	49281-0400-10	\$ 30.89	1569	\$ 48,466.41	\$31.75	4,826	\$153,226	\$32.63	\$157,472	
7.b				\$ 31.75	646	\$ 20,510.50						
08.	TENIVAC	Sanofi Pastuer	49281-0215-15	\$ -	0	\$ -	\$20.61	500	\$10,305	\$21.18	\$10,590	
8.b				\$ -	0	\$ -						
09.	TRUMENBA (Menb)	Pfizer	00005-0100-10	\$ 104.79	137	\$ 14,356.23	\$108.95	342	\$37,261	\$114.36	\$39,111	
9.b				\$ 108.95	51	\$ 5,556.45						
10.	Prevnar 13 (PCV 13)	Pfizer	00005-1971-02	\$ 131.77	15452	\$ 2,036,110.04	\$137.01	16,280	\$2,230,523	\$143.82	\$2,341,390	
10.b				\$ 137.01	5268	\$ 721,768.68						
11.	Bexsero (Menb)	GlaxoSmithKline	58160-0976-06	\$ 129.06	184	\$ 23,747.04	\$108.53	2,500	\$271,325	\$120.24	\$300,600	
11.b				\$ 103.40	757	\$ 78,274						
11.c				\$ 102.33	434	\$ 44,411						
12.	MENVEO (MCV4)	GlaxoSmithKline	58160-0955-09	\$ 92.10	316	\$ 29,104	\$76.00	5,058	\$384,408	\$95.78	\$484,455	
12.b				\$ 73.83	1903	\$ 140,498						
12.c				\$ 94.84	759	\$ 71,984						
13.	Infanrix (DTaP)	GlaxoSmithKline	58160-0810-11	\$ 18.19	461	\$ 8,386	\$18.67	499	\$9,316	\$19.16	\$9,561	
13.b				\$ 18.67	55	\$ 1,027						
14.	Pediarix (DTaP/Hep B/IPV)	GlaxoSmithKline	58160-0811-52	\$ 57.97	4827	\$ 279,821	\$59.05	5,027	\$296,844	\$60.71	\$305,189	
15.	Kinrix (DTaP/IPV)	GlaxoSmithKline	58160-0812-52	\$ 40.19	2181	\$ 87,654	\$41.31	2,778	\$114,759	\$42.46	\$117,954	
15.b				\$ 41.31	1088	\$ 44,945						
15.c			58160-0812-11	\$ 41.31	327	\$ 13,508						
16.	Havrix (Hep A)	GlaxoSmithKline	58160-0825-11	\$ 19.58	4953	\$ 96,980	\$20.52	11,407	\$234,072	\$21.11	\$240,802	
16.b			58160-0825-52	\$ 19.58	4835	\$ 94,669						
16.c			58160-0825-52	\$ 20.52	3151	\$ 64,659						
17.	Engerix-B (Hep B)	GlaxoSmithKline	58160-0820-52	\$ 14.03	2006	\$ 28,144	\$16.02	4,066	\$65,137	\$17.39	\$70,708	
17.b				\$ 16.02	3212	\$ 51,456						
18.	Rotarix (Rota)	GlaxoSmithKline	58160-0854-52	\$ 92.85	2653	\$ 246,331	\$94.69	3,096	\$293,160	\$97.51	\$301,891	

Maine CDC Vaccine Projection Data

18.b			\$ 94.69	1015	\$ 96,110						
19.	Boostrix (Tdap)	GlaxoSmithKline	58160-0842-11	\$ 31.37	4070	\$ 127,676	\$32.24	8,428	\$271,719	\$33.14	\$279,304
19.b			\$ 32.24	494	\$ 15,927						
19.c			58160-0842-51	\$ 32.24	987	\$ 31,821					
20.	HIBERIX	GlaxoSmithKline	58160-0818-11	\$ 9.65	34	\$ 328	\$9.46	32	\$303	\$9.46	\$303
20.b			\$ 9.46	15	\$ 142						
21.	VAQTA (Hep A)	Merck Sharp & Dohme Corp.	00006-4831-41	\$ 19.29	2953	\$ 56,963	\$19.66	3,054	\$60,042	\$20.61	\$62,943
21.b			00006-4095-02	\$ 19.66	511	\$ 10,046					
22.	RECOMBIVAX (Hep B)	Merck Sharp & Dohme Corp.	00006-4981-00	\$ 12.30	3543	\$ 43,579	\$12.30	7,522	\$92,521	\$12.53	\$94,251
22.b			00006-4903-02	\$ 12.30	1873	\$ 23,038					
23.	PedvaxHib (Hib)	Merck Sharp & Dohme Corp.	00006-4897-00	\$ 13.09	2928	\$ 38,328	\$13.21	3,605	\$47,622	\$13.51	\$48,704
23.b			\$ 13.21	1023	\$ 13,514						
24.	Gardasil (HPV9)	Merck Sharp & Dohme Corp.	00006-4119-03	\$ 168.10	2709	\$ 455,383	\$178.14	17,158	\$3,056,526	\$187.01	\$3,208,718
24.b			00006-4121-02	\$ 168.10	7194	\$ 1,209,311					
24.c			\$ 158.06	795	\$ 125,658						
24.d			\$ 178.14	3678	\$ 655,199						
25.	ROTATEQ (Rota)	Merck Sharp & Dohme Corp.	00006-4047-41	\$ 70.49	8767	\$ 617,986	\$70.49	6,337	\$446,695	\$71.88	\$455,504
26.	MMR II	Merck Sharp & Dohme Corp.	00006-4681-00	\$ 21.05	4862	\$ 102,345	\$21.22	5,931	\$125,856	\$21.71	\$128,762
26.b			\$ 21.22	2323	\$ 49,294						
27.	Proquad (MMRV)	Merck Sharp & Dohme Corp.	00006-4171-00	\$ 125.11	4850	\$ 606,784	\$131.40	8,578	\$1,127,149	\$137.51	\$1,179,561
27.b			\$ 131.40	1930	\$ 253,602						
28.	Pneumovax23 (Pedi)	Merck Sharp & Dohme Corp.	00006-4943-00	\$ 53.11	22	\$ 1,168	\$56.14	113	\$6,344	\$59.12	\$6,681
28.b			\$ 56.14	12	\$ 674						
29.	Varivax	Merck Sharp & Dohme Corp.	00006-4827-00	\$ 98.24	3640	\$ 357,594	\$104.09	6,541	\$680,853	\$109.26	\$714,670
29.b			\$ 104.09	230	\$ 23,941						
30.	Fluzone PF 0.5ml (>3 yrs)	Sanofi Pasteur	49281-0419-50	\$ 15.11	12830	\$ 193,861	\$13.76	3,000	\$41,271	\$13.55	\$40,650
31.	Fluzone PF 0.25ml (<3 yrs)	Sanofi Pasteur	49281-0519-25	\$ 15.11	8970	\$ 135,537	\$13.76	25,700	\$353,555	\$13.55	\$348,235
32.	FluMist Sprayer, 10-pack (2-18)	Astra Zeneca	66019-0306-10	\$ 18.88	2600	\$ 49,088	\$18.88	1,280	\$24,166	\$18.88	\$24,166
33.	Flulaval PF 0.5ml (6mth+)	GlaxoSmithKline	19515-0906-52	\$ 13.50	48330	\$ 652,455	\$13.50	32,100	\$433,350	\$13.75	\$441,375
34.					\$ 12,244,553			\$13,627,265	4.63%	\$14,258,134	
35.	<b>TOTAL</b>			<b>229,763</b>	<b>\$ 12,244,553</b>			<b>234,838</b>	<b>\$13,627,265</b>		<b>\$14,258,134</b>
36.									<b>Adjusted for overall utilization increase</b>		\$14,400,716
37.									<b>Adjusted for price increase</b>		<b>\$14,886,740</b>

**Maine Vaccine Board**  
**Estimated Covered Lives**  
**2021 Calendar Year Assessment Calculation**

Covered lives reported to KV for historical quarters:

	<u>Quarter</u>	<u>Monthly Average</u>	<u>Quarterly Change</u>	<u>12 Month Average</u>	
				<u>Lives</u>	<u>R12 Trend</u>
Q1 ending 9/30/2018	416,686	138,895	-0.85%	138,319	1.99%
Q2 ending 12/31/2018	417,763	139,254	0.26%	138,881	2.14%
Q3 ending 3/31/2019	422,914	140,971	1.23%	139,802	2.63%
Q4 ending 6/30/2019	419,499	139,833	-0.81%	139,739	1.70%
Q1 ending 9/30/2019	416,061	138,687	-0.82%	139,686	0.99%
Q2 ending 12/31/2019	415,098	138,366	-0.23%	139,464	0.42%
Q3 ending 3/31/2020	421,684	140,561	1.59%	139,362	-0.31%
Q4 ending 6/30/2020	419,608	139,869	-0.49%	139,371	-0.26%
Best Current Estimate				139,371	

Liquidity and Reserve Calculations

Column →	A	B	C
Line ↓			
Starting Balances			
01.	Cash Balance as of	4-Sep-2020	\$10,290,969
02.			
03.			
04.			\$10,290,969
Estimated Revenues			
05.	Final Quarterly Assessment (same as most recent collection)		\$3,340,251
06.			
07.			
08.			
09.			\$3,340,251
Expenditures / Allowances			
10.	<sup>1</sup> 1/3 of Annual Vaccine Cost Estimate		\$4,467,903
11.	<sup>1</sup> 1/3 of Annual Operating Budget Estimate		\$57,513
12.	Accounts Payables in Process per Maine CDC		\$1,766,196
13.	Pending Journal transfer per Maine CDC		\$756,672
14.			
15.			
16.			
17.			
18.	Total Expenditures		\$7,048,284
19.	Estimated Starting Balance January 1		\$6,582,936
20.	Target Months Cash (Non-Flu)	3.0	\$3,508,078
21.	Target Cash for Flu		\$854,426
22.	Target Cash Reserve (Line 20 + Line 21)		\$4,362,505
23.	Excess Cash Balance Above Cash target		\$2,220,431

Notes:

<sup>1</sup> This is 1/3 not 1/4 because September bills have not yet been paid.

**Maine Vaccine Board  
Vaccine Assessment Change Walk Down**

Column →	A	B	C	D	E	F	G
Line ↓	<b>2021 Calendar Year Assessment Calculation</b>						
			<u>Change from Prior Year</u>				<u>Walk</u>
	<u>Prior Year</u>	<u>2021</u>	<u>Aggregate \$</u>	<u>Distribution</u>	<u>Per Enrollee</u>		<u>Down</u>
01. Estimated vaccine costs	\$13,990,636	\$14,886,740	\$896,104	-4000.9%	\$0.71		9.0%
02. Total operational costs	\$172,540	\$176,773	\$4,233	-18.9%	\$0.00		0.0%
03. Bad debt and investment income	-\$55,274	-\$60,531	-\$5,256	23.5%	\$0.00		-0.1%
04. Net working capital reserve/carry forward	-\$2,191,731	-\$1,693,208	\$498,523	-2225.8%	\$0.40		5.0%
05. Projected assessment at old rate	<u>-\$1,910,462</u>	<u>-\$3,326,463</u>	<u>-\$1,416,001</u>	<u>6322.1%</u>	<u>-\$1.13</u>		<u>-14.2%</u>
06. Total	\$10,005,709	\$9,983,311	-\$22,398	100.0%	-\$0.02		-0.2%
07. Covered Lives	139,739	139,371	-368				0.3%
08. Total							0.0%
09. Assessment	\$7.96	\$7.96				\$0.00	0.0%